单选题：Text 2At 18, Ashanthi DeSilva of suburban Cleveland is a liv

Text 2
At 18, Ashanthi DeSilva of suburban Cleveland is a living symbol of one of the great intellectual achievements of the 20th century. Born with an extremely rare and usually fatal disorder that left her without a functioning immunesystem (the "bubble-boy disease", named after an earlier victim who was kept alive for years in a sterile plastictent), she was treated beginning in 1990 with a revolutionary new therapy that sought to correct the defect at its verysource, in the genes of her white blood cells. It worked. Although her last gene-therapy treatment was in 1992, sheis completely healthy with normal immune function, according to one of the doctors who treated her, W. FrenchAnderson of the University of Southern California. Researchers have long dreamed of treating diseases from hemo-philia to cancer by replacing mutant genes with normal ones. And the dreaming may continue for decades more.
"There will be a gene-based treatment for essentially every disease, " Anderson says, "within 50 years. "
It' s not entirely clear why medicine has been so slow to build on Anderson' s early success. The National Insti-tutes of Health budget office estimates it will spend $ 432 million on gene-therapy research in 2005, and there is noshortage of promising leads. The therapeutic genes are usually delivered through viruses that don' t cause human dis-ease. "The virus is sort of like a Trojan horse, " says Ronald Crystal of New York Presbyterian/Weill Cornell Med-ical College. "The cargo is the gene. "
At the University of Pennsylvania' s Abramson Cancer Center, immunologist Carl June recently treated HIV pa-tients with a gene intended to help their cells resist the infection. At Cornell University, researchers are pursuinggene-based therapies for Parkinson' s disease and a rare hereditary disorder that destroys children' s brain cells. AtStanford University and the Children' s Hospital of Philadelphia, researchers are trying to figure out how to help pa-tients with hemophilia who today must inject themselves with expensive clotting drugs for life. Animal experimentshave shown great promise.
But somehow, things get lost in the translation from laboratory to patient. In human trials of the hemophiliatreatment, patients show a response at first, but it fades over time. And the field has still not recovered from the set-back it suffered in 1999, when Jesse Gelsinger, an 18-year-old with a rare metabolic disorder, died after receivingan experimental gene therapy at the University of Pennsylvania. Some experts worry that the field will be tarnishedfurther if the next people to benefit are not patients but athletes seeking an edge. This summer, researchers at theSalk Institute in San Diego said they had created a "marathon mouse" by implanting a gene that enhances running a-bility; already, officials at the World Anti-Doping Agency are preparing to test athletes for signs of "gene doping".
But the principle is the same, whether you' re trying to help a healthy runner run faster or allow a muscular-dystro-phy patient to walk. "Everybody recognizes that gene therapy is a very good idea, " says Crystal. "And eventuallyit' s going to work. "
根据以上材料，回答题。
The case of Ashanthi Desilva is mentioned in the text to__________. A．show the promise of gene-therapy
B．give an example of modem treatment for fatal diseases
C．introduce the achievement of Anderson and his team
D．explain how gene-based treatment works